Y Intercept Hong Kong Ltd Makes New Investment in Replimune Group, Inc. $REPL

Y Intercept Hong Kong Ltd purchased a new stake in Replimune Group, Inc. (NASDAQ:REPL) in the first quarter, Holdings Channel reports. The firm purchased 68,978 shares of the company’s stock, valued at approximately $528,000.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Fcpm Iii Services B.V. boosted its holdings in Replimune Group by 6.4% in the third quarter. Fcpm Iii Services B.V. now owns 4,158,368 shares of the company’s stock worth $17,424,000 after purchasing an additional 248,672 shares during the period. Jefferies Financial Group Inc. bought a new stake in Replimune Group during the fourth quarter valued at $6,942,000. Persistent Asset Partners Ltd acquired a new stake in shares of Replimune Group during the fourth quarter worth $598,000. Commodore Capital LP acquired a new stake in shares of Replimune Group during the fourth quarter worth $13,851,000. Finally, Erste Asset Management GmbH lifted its position in shares of Replimune Group by 30.1% in the 4th quarter. Erste Asset Management GmbH now owns 2,120,000 shares of the company’s stock worth $20,619,000 after buying an additional 490,000 shares during the last quarter. 92.53% of the stock is owned by institutional investors and hedge funds.

Replimune Group Trading Down 9.6%

Replimune Group stock opened at $9.94 on Tuesday. The company has a quick ratio of 4.79, a current ratio of 4.79 and a debt-to-equity ratio of 0.63. The firm has a 50-day moving average price of $8.17 and a two-hundred day moving average price of $7.38. The firm has a market capitalization of $834.36 million, a price-to-earnings ratio of -2.94 and a beta of 0.86. Replimune Group, Inc. has a 52-week low of $1.50 and a 52-week high of $13.24.

Replimune Group (NASDAQ:REPL) last posted its earnings results on Monday, June 29th. The company reported ($0.76) EPS for the quarter, missing the consensus estimate of ($0.66) by ($0.10). Sell-side analysts expect that Replimune Group, Inc. will post -2.29 earnings per share for the current year.

Analyst Ratings Changes

REPL has been the subject of several research reports. Cantor Fitzgerald lowered shares of Replimune Group from an “overweight” rating to a “hold” rating in a report on Monday, April 13th. JPMorgan Chase & Co. raised shares of Replimune Group from a “neutral” rating to an “overweight” rating and set a $17.00 target price on the stock in a report on Friday, June 26th. Wall Street Zen upgraded Replimune Group from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 23rd. Jefferies Financial Group reaffirmed a “hold” rating and set a $2.00 target price (down from $13.00) on shares of Replimune Group in a report on Monday, April 13th. Finally, BMO Capital Markets upgraded Replimune Group from an “underperform” rating to an “outperform” rating and set a $16.00 price target on the stock in a research report on Tuesday, June 30th. Two research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $8.12.

Insider Activity

In related news, insider Christopher Sarchi sold 12,000 shares of the stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $9.24, for a total value of $110,880.00. Following the completion of the transaction, the insider directly owned 180,962 shares of the company’s stock, valued at $1,672,088.88. This represents a 6.22% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 5.20% of the company’s stock.

Replimune Group Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.